Search results
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $1,229.00
ETF DAILY NEWS· 3 days agoRegeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its target price upped by Royal Bank of Canada from $1,200.00 to $1,229.00 ...
Insider Selling: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) CEO Sells 9,064 Shares of Stock
ETF DAILY NEWS· 2 days agoRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) CEO Leonard S. Schleifer sold 9,064 shares of the company’s stock in ...
Jacobi Capital Management LLC Boosts Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
ETF DAILY NEWS· 4 days agoJacobi Capital Management LLC grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 10.5% in the 4th quarter ...
Investors in Regeneron Pharmaceuticals (NASDAQ:REGN) have seen stellar returns of 220% over the past...
Simply Wall St. via Yahoo Finance· 2 days agoBut on a lighter note, a good company can see its share price rise well over 100%. Long term ...
Westwood Holdings Group Inc. Has $11.22 Million Stock Position in Regeneron Pharmaceuticals, Inc. (...
ETF DAILY NEWS· 7 days agoWestwood Holdings Group Inc. lowered its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 1.4% during the fourth ...
Regeneron holds Buy rating and price target from TD Cowen By Investing.com
Investing.com· 2 days agoOn Friday, TD (TSX:TD) Cowen maintained a Buy rating on shares of Regeneron (NASDAQ:REGN) ...
...Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN - ...
Benzinga· 18 hours agoNEW YORK, June 15, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron ...
Regeneron CEO Leonard Schleifer sells over $25 million in company stock By Investing.com
Investing.com· 2 days agoRegeneron (NASDAQ:REGN) Pharmaceuticals, Inc. (NASDAQ:REGN) has reported a series of transactions by...
RBC lifts Regeneron stock PT to $1,229 on higher sales estimetes of Dupixent By Investing.com
Investing.com· 4 days agoOn Wednesday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) saw an increase in its price target to...
...Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market - Regeneron ...
Benzinga· 3 days agoAnalyst projects Regeneron's Dupixent to drive COPD sales surge, envisioning $20B market by 2026 on larger addressable market.